中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物化学研究室
Enantiospecific synthesis of all four Stereoisomers of novel bicyclic arylacetamides as kappa-Opioid agonists

文献类型：期刊论文

作者Long, YQ; Mou, QY; Qiu, DP; Wu, RQ
刊名CHINESE JOURNAL OF CHEMISTRY
出版日期2002-10
卷号20期号:10页码:1073-1079
关键词kappa-Opioid receptor agonist bicyclic arylacetamide conformational restriction enantiospecific synthesis
ISSN号1001-604X
文献子类Article
英文摘要Conformationally constrained bicyclic derivatives of the potent and selective kappa-oploid receptor agonist 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S) -1-phenyl-2-(1-pyrrolidinyl)-ethyl] acetamide (3, ICI-199, 441) were designed to explore the effect of the conformational restriction and stereochemistry of the pharmacophoric ethylenediamine incorporated into the pyrrolidine on the affinity and x-selectivity. A facile enantiospecific synthetic route was established to afford all four stereoisomers starting from readily available ammo acids through mild cyclization and amide formation.
WOS关键词HIGHLY POTENT ; RECEPTORS ; SELECTIVITY ; AFFINITY ; AMINES
WOS研究方向Chemistry
语种英语
WOS记录号WOS:000178644700027
出版者SCIENCE CHINA PRESS
源URL[http://119.78.100.183/handle/2S10ELR8/274325]  
专题药物化学研究室
通讯作者Long, YQ
作者单位Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Materia Medica, Shanghai 200031, Peoples R China
推荐引用方式
GB/T 7714		 Long, YQ,Mou, QY,Qiu, DP,et al. Enantiospecific synthesis of all four Stereoisomers of novel bicyclic arylacetamides as kappa-Opioid agonists[J]. CHINESE JOURNAL OF CHEMISTRY,2002,20(10):1073-1079.
APA Long, YQ,Mou, QY,Qiu, DP,&Wu, RQ.(2002).Enantiospecific synthesis of all four Stereoisomers of novel bicyclic arylacetamides as kappa-Opioid agonists.CHINESE JOURNAL OF CHEMISTRY,20(10),1073-1079.
MLA Long, YQ,et al."Enantiospecific synthesis of all four Stereoisomers of novel bicyclic arylacetamides as kappa-Opioid agonists".CHINESE JOURNAL OF CHEMISTRY 20.10(2002):1073-1079.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。